Market closedNon-fractional

Viracta Therapeutics/VIRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Viracta Therapeutics

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Ticker

VIRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cardiff, United States

Employees

40

VIRX Metrics

BasicAdvanced
$21M
Market cap
-
P/E ratio
-$1.24
EPS
0.39
Beta
-
Dividend rate
$21M
0.39
1.354
1.308
170.19
-14.22%
-51.49%
-154.33%
3.78
3.78
-0.572
-7.69%
-64.07%

What the Analysts think about VIRX

Analyst Ratings

Majority rating from 4 analysts.
Buy

VIRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$9.1M
-33.58%
Profit margin
0.00%
NaN%

VIRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 34.75%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.33
-$0.35
-$0.23
-
Expected
-$0.29
-$0.31
-$0.31
-$0.35
-$0.36
Surprise
10.34%
8.20%
12.90%
-34.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Viracta Therapeutics stock?

Viracta Therapeutics (VIRX) has a market cap of $21M as of July 15, 2024.

What is the P/E ratio for Viracta Therapeutics stock?

The price to earnings (P/E) ratio for Viracta Therapeutics (VIRX) stock is 0 as of July 15, 2024.

Does Viracta Therapeutics stock pay dividends?

No, Viracta Therapeutics (VIRX) stock does not pay dividends to its shareholders as of July 15, 2024.

When is the next Viracta Therapeutics dividend payment date?

Viracta Therapeutics (VIRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Viracta Therapeutics?

Viracta Therapeutics (VIRX) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Viracta Therapeutics stock

Buy or sell Viracta Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing